Thor Medical ASA (OB: TRMED)
Health Care · Biotechnology · NO
Nkr6.05
+11.42% today · +115.7% 1Y
Thor Medical ASA (OB: TRMED) operates in the Biotechnology industry within the Health Care sector. The company is valued at $230.72M and employs 18 people.
Over the last twelve months the share price has gained 115.7%, trading between 2.52 and 6.62.
Tweenvest scores Thor Medical ASA across four factors: quality 39/100. Its strongest factor is quality.
TRMED price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $230.72M
- Revenue (TTM)
- $83.23K
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- -0.23
- 52-week high
- Nkr6.62
- 52-week low
- Nkr2.52
- Avg volume (3M)
- —
- Shares outstanding
- 360.00M
- Employees
- 18
- Next earnings
- —
About Thor Medical ASA
Established in 2017, Thor Medical ASA, with its headquarters in Oslo, Norway, specializes in the development and provision of alpha-particle emitters for oncology treatments within Norway.
- ISIN
- NO0010597883
- Founded
- 2009
- Listed since
- Mar 23, 2015
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.07 | +0.59% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.57 | -0.06% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.46 | +1.17% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.70 | +0.93% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.49 | +0.60% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.83 | +13.64% |
Figures last refreshed Aug 18, 2026.